Research programme: cystic fibrosis transmembrane conductance regulator modulators - Vertex PharmaceuticalsAlternative Names: C-18; CF-106951; CFcor-325; VRT-325; VRT-534
Latest Information Update: 10 Sep 2013
At a glance
- Originator Vertex Pharmaceuticals
- Class Piperazines; Quinazolines; Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cystic fibrosis